2 completed. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow etesevimab: new trials by email Literature Review of etesevimab trials Research Report on etesevimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness Bamlanivimab, Etesevimab, Placebo - COVID-19 | Phase 2 | Completed | Eli Lilly and Company | 1755 | 2020-10-29 | 2022-07-01 |
| A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness LY3819253, LY3832479, LY3853113 - COVID-19 | Phase 2 / Phase 3 | Completed | Eli Lilly and Company | 3307 | 2020-06-17 | 2024-04-11 |
COVID-19 (2)
United States (2) · Argentina (1) · Puerto Rico (1)
PMID 34374951, PMID 34473343, PMID 35713300, PMID 33113295, PMID 33475701, PMID 34260849, PMID 34346827, PMID 34718468, PMID 35493124, PMID 37329415, PMID 38291279, PMID 39230829